Eling Pharmaceutical: Notice on Wholly Owned Subsidiary Formulation Products Obtaining U.S. FDA Approval Numbers
Eling Pharmaceutical: Announcement on the inclusion of the company\'s drugs in the “National Medical Insurance Catalogue” through negotiations
Eling Pharmaceutical: Record of Investor Relations Activities for October 29, 2024
Eling Pharmaceutical: Report for the third quarter of 2024
Eling Pharmaceutical: Notice on Acceptance of Clinical Trial Applications for Innovative Chemical Drug G201-Na Capsules
Eling Pharmaceutical: Record of Investor Relations Activities on October 15, 2024
Eling Pharmaceutical: Announcement on attending the 2024 Online Group Reception Day for Investors of Listed Companies in Hebei and the 2024 Semi-Annual Report Results Briefing
Eling Pharmaceutical: Announcement on the acceptance of the application for clinical trials of the new traditional Chinese medicine Lianhua Yuping granular drug
Eling Pharmaceutical: Announcement on Release of the Pledge of Part of the Actual Controller\'s Shares
Eling Pharmaceutical: Announcement on the actual controller\'s partial share pledge
Eling Pharmaceutical: Investor Relations Activity Record Form for August 28, 2024
Eling Pharmaceutical: Semi-Annual Report 2024
Eling Pharmaceutical: Announcement of Resolutions of the Supervisory Board in the Semi-Annual Report
Eling Pharmaceutical: Announcement of Board Resolutions of the Semi-Annual Report
Eling Pharmaceutical: Special Report of the Board of Directors of Eling Pharmaceutical on the Deposit and Use of Funds Raised for the Semi-Annual Period of 2024
Eling Pharmaceutical: Summary of the 2024 Semi-Annual Report
Eling Pharmaceutical: Semi-annual Non-Operating Capital Occupancy and Other Related Capital Transactions Summary
Eling Pharmaceutical: 2024 Semi-Annual Financial Report
Shijiazhuang Yiling Pharmaceutical: 2023 Annual Equity Distribution Implementation Announcement
Shijiazhuang Yiling Pharmaceutical: 2024 Interim Performance Forecast
No Data
No Data